JOINT-STOCK COMPANY "R-FARM" will carry out KI olokizumaba according to the new indication

<1> Group "R-Farm" got permission Ministry of Health of the Russian Federation for carrying out KI of a preparation of Artlegia (olokizumab) according to the new indication – idiopathic pulmonary fibrosis. According to GRLS, permission is given out on carrying out KI in 14 medical centers, however JOINT-STOCK COMPANY "R-FARM" plans to involve 11 clinics. The beginning of the II-III phases of researches is planned for 2023. Now the main indication olokizumaba – rheumatoid arthritis. It is planned to estimate efficiency olokizumaba in a dose of 64 mg at hypodermic introduction each four weeks in comparison with placebo at patients with progressing fibroziruyushchy interstitsialny diseases of lungs...